NCT04430179View on ClinicalTrials.gov

Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 17, 2020

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis
Interventions
DRUG

Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]

300 mg every other week for 24 weeks

OTHER

Placebo

No active drug

Trial Locations (1)

33613

University of South Florida Asthma, Allergy and Immunology, Tampa

All Listed Sponsors
lead

University of South Florida

OTHER